NEW YORK (
CHANGE IN RATINGS
downgraded at UBS to Neutral from Buy, UBS said. $37 price target. Valuation call.
downgraded at JP Morgan from Overweight to Neutral, JP Morgan said. Valuation call, as the company lags near-term catalysts.
upgraded at Deutsche from Hold to Buy, Deutsche Bank said. $108 price target. Market is not yet pricing in the company's above-average growth.
downgraded at Oppenheimer to Perform from Outperform, Oppenheimer said. Too early to call AP26113 winner.
downgraded at Goldman from Buy to Neutral, Goldman Sachs said. Valuation call, based on a $28 price target.
Check Point Software
upgraded at JP Morgan from Neutral to Overweight, JP Morgan said. $50 price target. Investor expectations are low, but the company generates consistent cash flow.
upgraded at Goldman to Buy, Goldman Sachs said. Company delivers above-average growth and should soon see a double-digit price hike.
rated new Hold at Miller Tabak. Valuation call, based on a $34 price target.
upgraded at JP Morgan from Underweight to Overweight, JP Morgan said. New analyst has a $71 price target. Company is facing favorable regulations and pays an above-average dividend.
downgraded at Goldman from Buy to Neutral, Goldman Sachs said. Valuation call, as the stock has outperformed its peers by 11% year-to-date.
downgraded at BMO from Outperform to Market Perform, BMO Capital said. $130 price target. Company is seeing slower core business growth and recently announced some management changes.
downgraded at Baird from Outperform to Neutral, Robert Baird said. $30 price target. Company is facing increased competition from EMC and others.
downgraded at Sterne to Neutral, Sterne Agee said. Valuation call, as the stock has outperformed its peers in recent years.
Omega Healthcare Investors
downgraded at Jefferies to Hold from Buy, Jefferies said. Fiscal cliff looms.
downgraded at Argus from Buy to Hold, Argus said. Company faces growth headwinds in the near term.
downgraded at Goldman from Neutral to Sell, Goldman Sachs said. $52 price target. Company has below-average earnings and dividend growth.
downgraded at Jefferies to Hold from Buy, Jefferies said. $66 price target. Fiscal cliff looms.
STOCK COMMENTS / EPS CHANGES
estimates, target cut at Guggenheim. Shares of APA now seen reaching $111, according to Guggenheim. Estimates also reduced, given increased fleet downtime. Buy rating.
estimates cut at Dahlman through 2013, Dahlman Rose said. Company is leveraged to slower growth in North America. Buy rating and $50 price target.
numbers raised at Citigroup. Shares of BTU now seen reaching $33, Citigroup said. Estimates also increased on improving cost and capex management. Buy rating.
Peabody Energy numbers boosted at Credit Suisse. Shares of BTU now seen reaching $33, according to Credit Suisse. Estimates also upped, as the company continues to execute well. Outperform rating.
estimates, target cut at Credit Suisse. Shares of CAT now seen reaching $108, according to Credit Suisse. Estimates also reduced, given the company's new guidance. Outperform rating.
numbers raised at Guggenheim. Shares of COF now seen reaching $72, according to Guggenheim. Estimates also increased, as the company is realizing higher margins. Buy rating.
target raised at Oppenhiemer to $80, Oppenheimer said. Raising target ahead of quarterly results. Outperform rating.
numbers cut at UBS. Shares of FCX now seen reaching $47, UBS said. Estimates also lowered as Grasberg guidance marginally lower. Buy rating.
Freeport-McMoran numbers reduced at JP Morgan. Shares of FCX now seen reaching $63, according to JP Morgan. Estimates also cut, given lower realized gold volumes. Overweight rating.
numbers cut at Morgan Stanley. FRX estimates were reduced through 2013, Morgan Stanley said. Company is seeing slower sales growth. Equal-weight rating and new $35 price target.
numbers lowered at Credit Suisse. Shares of HMA now seen reaching $10, according to Credit Suisse. Estimates also cut, given weaker volumes and rising costs. Outperform rating.
cut from Conviction Buy List at Goldman. MNST was removed from the Conviction Buy list, according to Goldman Sachs. $62 price target. Stock will likely be range-bound, given regulatory and legal concerns.
Monster Beverage target cut at Citigroup to $50, Citigroup said. Stock falls on fatality report. Neutral rating.
numbers lowered at Jefferies. Shares of STI now seen reaching $32, Jefferies said. Estimates also lowered on deleveraging weighing on NII. Buy rating.
estimates reduced at Dahlman through 2013, Dahlman Rose said. North American land business continues to deteriorate. Buy rating and $92 price target.
estimates, target cut at Credit Suisse. STI estimates were reduced through 2013, Credit Suisse said. Company is not cutting costs fast enough to keep up with lower sales. Outperform rating and new $33 price target.
numbers cut at JP Morgan. WDC estimates were reduced through 2014, JP Morgan said. Company lowered its guidance, given slower PC growth. Neutral rating and new $38 price target.
numbers raised at UBS. Shares of ZION now seen reaching $21.50, UBS said. Estimates also increased on mitigating margin headwinds. Neutral rating.
>To submit a news tip, email:
READERS ALSO LIKE:
and become a fan on
This article was written by a staff member of TheStreet.